Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pieris And Seattle Strike IO Deal

Executive Summary

Pieris secures another deal for its novel Anticalin technology – this time with Seattle in immuno-oncology.

You may also be interested in...



Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie

Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.

AstraZeneca Taps Pieris For Inhaled Asthma Anticalins

AstraZeneca is to pay $57.5m to get its hands on biotech Pieris Pharmaceuticals' Anticalin technology to bolster its early stage respiratory portfolio, with a lead product candidate already being prepared for Phase I.

ESMO: Sanofi/Regeneron’s Latecomer Anti-PD-1 Libtayo Looking Likely In NSCLC

Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel